 [1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[34m                Passages:[0m
[34m                [0m[1;34m1[0m[34m. Drug CARBAMAZEPINE: DO-NOT-KNOW[0m

[34mThe question asked was whether CARBAMAZEPINE increases or decreases the risk of mortality after myocardial infarction. I attempted to consult FDAHandler for information regarding the effects of [0m
[34mCARBAMAZEPINE on mortality risk after myocardial infarction, but I did not receive any data or response that could inform an answer. Without specific information from FDA labels, it is not possible to[0m
[34mdetermine the effect of CARBAMAZEPINE on mortality risk following a myocardial infarction. Therefore, the answer must be [0m[34m"DO-NOT-KNOW."[0m
[34m                ---------[0m
[34m                Does the carbamazepine category of drugs increase the risk of[0m
[34m                mortality after myocardial infarction, decrease it, or is there no clear effect?[0m
[34m            [0m
 [1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [31m Entity.AGENT [0m
*[1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the carbamazepine category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"The passage provided does not contain any specific information about the effects of carbamazepine on mortality risk after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"The passage explicitly states that the answer must be 'DO-NOT-KNOW' due to the lack of data or response from FDA labels."[0m[32m,[0m
[32m      [0m[32m"Without evidence from clinical trials, studies, or FDA labels, it is not possible to determine the effect of carbamazepine on mortality risk following a myocardial infarction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"There is no clear effect of the carbamazepine category of drugs on the risk of mortality after myocardial infarction due to the lack of available information."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the carbamazepine category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"The passage provided does not contain any specific information about the effects of carbamazepine on mortality risk after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"The passage explicitly states that the answer must be 'DO-NOT-KNOW' due to the lack of data or response from FDA labels."[0m[34m,[0m
[34m      [0m[34m"Without evidence from clinical trials, studies, or FDA labels, it is not possible to determine the effect of carbamazepine on mortality risk following a myocardial infarction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"There is no clear effect of the carbamazepine category of drugs on the risk of mortality after myocardial infarction due to the lack of available information."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the carbamazepine category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. The passage provided does not contain any specific information about the effects of carbamazepine on mortality risk after myocardial infarction.[0m
[1;31m2[0m[31m. The passage explicitly states that the answer must be [0m[31m'DO-NOT-KNOW'[0m[31m due to the lack of data or response from FDA labels.[0m
[1;31m3[0m[31m. Without evidence from clinical trials, studies, or FDA labels, it is not possible to determine the effect of carbamazepine on mortality risk following a myocardial infarction.[0m
[31m        -----[0m
[31m        Final answer: There is no clear effect of the carbamazepine category of drugs on the risk of mortality after myocardial infarction due to the lack of available information.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The user's reasoning is flawed because it does not follow the guidelines provided. According to the instructions, if there is an absence of information related to a condition in the [0m
[32mFDA data for all drugs in a category, the conclusion should be that there is no effect for that drug on the risk of the condition. The user's statement that the answer must be 'DO-NOT-KNOW' is [0m
[32mincorrect. Instead, the absence of information should lead to the conclusion that there is no effect. Therefore, the final answer should state that carbamazepine has no effect on the risk of mortality[0m
[32mafter myocardial infarction, not that there is no clear effect."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The user's reasoning is flawed because it does not follow the guidelines provided. According to the instructions, if there is an absence of information related to a condition in the [0m
[34mFDA data for all drugs in a category, the conclusion should be that there is no effect for that drug on the risk of the condition. The user's statement that the answer must be 'DO-NOT-KNOW' is [0m
[34mincorrect. Instead, the absence of information should lead to the conclusion that there is no effect. Therefore, the final answer should state that carbamazepine has no effect on the risk of mortality[0m
[34mafter myocardial infarction, not that there is no clear effect."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The user's reasoning is flawed because it does not follow the guidelines provided. According to the instructions, if there is an absence of information related to a condition in the [0m
[31mFDA data for all drugs in a category, the conclusion should be that there is no effect for that drug on the risk of the condition. The user's statement that the answer must be [0m[31m'DO-NOT-KNOW'[0m[31m is [0m
[31mincorrect. Instead, the absence of information should lead to the conclusion that there is no effect. Therefore, the final answer should state that carbamazepine has no effect on the risk of mortality[0m
[31mafter myocardial infarction, not that there is no clear effect.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the carbamazepine category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"The passage provided does not contain any specific information about the effects of carbamazepine on mortality risk after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"According to the guidelines, if there is an absence of information related to a condition in the FDA data for all drugs in a category, the conclusion should be that there is no effect for that [0m
[32mdrug on the risk of the condition."[0m[32m,[0m
[32m      [0m[32m"Therefore, the correct interpretation of the passage is that carbamazepine has no effect on the risk of mortality after myocardial infarction, not that the effect is unknown."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The carbamazepine category of drugs has no effect on the risk of mortality after myocardial infarction due to the lack of available information indicating an increase or decrease in [0m
[32mrisk."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the carbamazepine category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"The passage provided does not contain any specific information about the effects of carbamazepine on mortality risk after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"According to the guidelines, if there is an absence of information related to a condition in the FDA data for all drugs in a category, the conclusion should be that there is no effect for that [0m
[34mdrug on the risk of the condition."[0m[34m,[0m
[34m      [0m[34m"Therefore, the correct interpretation of the passage is that carbamazepine has no effect on the risk of mortality after myocardial infarction, not that the effect is unknown."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The carbamazepine category of drugs has no effect on the risk of mortality after myocardial infarction due to the lack of available information indicating an increase or decrease in [0m
[34mrisk."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the carbamazepine category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. The passage provided does not contain any specific information about the effects of carbamazepine on mortality risk after myocardial infarction.[0m
[1;31m2[0m[31m. According to the guidelines, if there is an absence of information related to a condition in the FDA data for all drugs in a category, the conclusion should be that there is no effect for that drug[0m
[31mon the risk of the condition.[0m
[1;31m3[0m[31m. Therefore, the correct interpretation of the passage is that carbamazepine has no effect on the risk of mortality after myocardial infarction, not that the effect is unknown.[0m
[31m        -----[0m
[31m        Final answer: The carbamazepine category of drugs has no effect on the risk of mortality after myocardial infarction due to the lack of available information indicating an increase or decrease[0m
[31min risk.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The user's revised reasoning is correct. It follows the guidelines that state the absence of information in the FDA data for all drugs in a category should lead to the conclusion that[0m
[32mthere is no effect on the risk of the condition. The final answer appropriately states that carbamazepine has no effect on the risk of mortality after myocardial infarction due to the lack of [0m
[32mavailable information indicating an increase or decrease in risk."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The user's revised reasoning is correct. It follows the guidelines that state the absence of information in the FDA data for all drugs in a category should lead to the conclusion that[0m
[34mthere is no effect on the risk of the condition. The final answer appropriately states that carbamazepine has no effect on the risk of mortality after myocardial infarction due to the lack of [0m
[34mavailable information indicating an increase or decrease in risk."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The user's revised reasoning is correct. It follows the guidelines that state the absence of information in the FDA data for all drugs in a category should lead to the conclusion [0m
[31mthat there is no effect on the risk of the condition. The final answer appropriately states that carbamazepine has no effect on the risk of mortality after myocardial infarction due to the lack of [0m
[31mavailable information indicating an increase or decrease in risk.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mcategory_effect_tool[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"category_effect_tool"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"label"[0m[32m: [0m[32m"no-effect"[0m[32m,[0m
[32m    [0m[32m"confidence"[0m[32m: [0m[1;32m0.9[0m[32m,[0m
[32m    [0m[32m"probability"[0m[32m: [0m[1;32m0[0m[32m,[0m
[32m    [0m[32m"frequency"[0m[32m: [0m[32m"none"[0m[32m,[0m
[32m    [0m[32m"evidence"[0m[32m: [0m[32m"weak"[0m[32m,[0m
[32m    [0m[32m"justification"[0m[32m: [0m[32m"The absence of information in the FDA data for the carbamazepine category of drugs regarding the risk of mortality after myocardial infarction leads to the conclusion that there [0m
[32mis no effect. The confidence is high due to the adherence to the guidelines provided, but the evidence is considered weak because it is based on the absence of data rather than positive evidence of no[0m
[32meffect."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-carbamazepine[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mcategory_effect_tool[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m
